A method for measuring blood coagulation, including: preparing a reaction solution including a plasma specimen, a blood coagulation activator, and at least one of amino-guanidine and an acid addition salt thereof; and measuring blood coagulation time by detecting a turbidity change in the reaction solution.

A method for measuring blood coagulation, including: preparing a reaction solution including a plasma specimen, a blood coagulation activator, and at least one of amino-guanidine and an acid addition salt thereof; and measuring blood coagulation time by detecting a turbidity change in the reaction solution.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.

A device for monitoring the spatial and temporal dynamics of thrombin that includes a temperature-controlled sealed chamber with a transparent window and a light trap, the chamber being filled with a fluid medium and designed to accommodate a cuvette containing a test sample of blood plasma, and a coagulation activating insert placed into the cuvette, at least one illumination source and at least one first irradiation source and at least one second irradiation source capable of exciting a fluorescence signal of a special marker that forms in the sample during cleavage of a fluorogenic substrate, a camera, a pressure adjustment element capable of maintaining a pressure inside the chamber, the at least one first irradiation source provides irradiation of the sample in a direction perpendicular to the cuvette, and the at least one second irradiation source provides irradiation of the sample at an angle to the cuvette.

A device for monitoring the spatial and temporal dynamics of thrombin that includes a temperature-controlled sealed chamber with a transparent window and a light trap, the chamber being filled with a fluid medium and designed to accommodate a cuvette containing a test sample of blood plasma, and a coagulation activating insert placed into the cuvette, at least one illumination source and at least one first irradiation source and at least one second irradiation source capable of exciting a fluorescence signal of a special marker that forms in the sample during cleavage of a fluorogenic substrate, a camera, a pressure adjustment element capable of maintaining a pressure inside the chamber, the at least one first irradiation source provides irradiation of the sample in a direction perpendicular to the cuvette, and the at least one second irradiation source provides irradiation of the sample at an angle to the cuvette.

The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.

The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.

The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.

Provided is a method for purifying α-thrombin and for quantifying α-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified α-thrombin. The method can also be used for purification and/or quantification of β-thrombin.